LivingGLP1
Descriptive only

Systolic blood pressure change

Type 2 diabetes (adults)

weeks 64 to 130 (target week 104)Not stated by the trialsDoses of a drug pooledMean differenceSeparate part 3 of a disconnected network
1
Randomized trials
2
Treatments
0
Participants
2
Trial arms

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
EXEN_SCSTANDARD_CARE
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
Baseline effect modifiers and prognostic factors per trial
TrialBaseline BMI or body weight (kg/m2)
effect modifier, prognostic factor; 1 of 1
NCT01776788
S002224
24.96

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

No comparability concerns were found.

Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
NCT01776788104.36otherHbA1c adjusted for baseline by ANCOVA, participants still in remissionnot statednot statednot statednot statednot statedopen_labelindustry2012age 30 to 70; newly diagnosed drug naive; FPG 7.0 to 16.7 mmol/L; BMI 20 to 35

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
NCT01776788A1STANDARD_CARE104.36arm, final128.4003.342R0024844:Table 1
NCT01776788A2EXEN_SC104.36arm, final125.0002.296R0024844:Table 1

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab